What is Kiora Pharma's earnings per share (EPS)?

Kiora Pharma (KPHMW) reported diluted earnings per share of $0.87 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kiora Pharma Financials

KPHMW

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Kiora Pharma (KPHMW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 84/100

Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Kiora Pharma has an operating margin of 28.1%, meaning the company retains $28 of operating profit per $100 of revenue. This strong profitability earns a score of 85/100, reflecting efficient cost management and pricing power.

Leverage

Kiora Pharma carries a low D/E ratio of 0.42, meaning only $0.42 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 4.94, Kiora Pharma holds $4.94 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 99/100.

Cash Flow

100

Kiora Pharma converts 53.4% of revenue into free cash flow ($8.6M). This strong cash generation earns a score of 100/100.

Returns

Kiora Pharma's ROE of 14.0% shows moderate profitability relative to equity, earning a score of 42/100. This is up from -204.8% the prior year.

Piotroski F-Score Neutral

6/9

Kiora Pharma passes 6 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.38x

For every $1 of reported earnings, Kiora Pharma generates $2.38 in operating cash flow ($8.6M OCF vs $3.6M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

210.3x

Kiora Pharma earns $210.3 in operating income for every $1 of interest expense ($4.5M vs $21K). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$16.0M

5Y CAGR+42.9%

Kiora Pharma generated $16.0M in revenue in fiscal year 2024.

EBITDA

$4.5M

YoY+136.1%

Kiora Pharma's EBITDA was $4.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 136.1% from the prior year.

Net Income

$3.6M

YoY+128.7%

Kiora Pharma reported $3.6M in net income in fiscal year 2024. This represents an increase of 128.7% from the prior year.

EPS (Diluted)

$0.87

Kiora Pharma earned $0.87 per diluted share (EPS) in fiscal year 2024. This represents an increase of 103.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$8.6M

YoY+189.5%

Kiora Pharma generated $8.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 189.5% from the prior year.

Cash & Debt

$3.8M

YoY+54.5%

5Y CAGR+0.1%

10Y CAGR+36.7%

Kiora Pharma held $3.8M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

Kiora Pharma had 3M shares outstanding in fiscal year 2024. This represents an increase of 250.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

28.1%

Kiora Pharma's operating margin was 28.1% in fiscal year 2024, reflecting core business profitability.

Net Margin

22.4%

5Y CAGR+286.7pp

Kiora Pharma's net profit margin was 22.4% in fiscal year 2024, showing the share of revenue converted to profit.

Return on Equity

14.0%

YoY+218.8pp

5Y CAGR+121.1pp

Kiora Pharma's ROE was 14.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 218.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$7.8M

YoY+94.7%

5Y CAGR+7.8%

10Y CAGR+30.9%

Kiora Pharma invested $7.8M in research and development in fiscal year 2024. This represents an increase of 94.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$6K

Kiora Pharma invested $6K in capex in fiscal year 2024, funding long-term assets and infrastructure.

KPHMW Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	$16.0M	$0	N/A	$0-100.0%	$12K-99.6%	$2.7M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$7.8M+94.7%	$4.0M+16.8%	$3.4M-35.5%	$5.4M+50.0%	$3.6M-33.8%	$5.4M
SG&A Expenses	$5.5M+18.9%	$4.7M-43.7%	$8.3M+55.5%	$5.3M+14.3%	$4.7M+5.7%	$4.4M
Operating Income	$4.5M+135.8%	-$12.6M-2.3%	-$12.3M+13.5%	-$14.2M-107.3%	-$6.9M	N/A
Interest Expense	$21K+92.7%	$11K+29.5%	$9K+25.5%	$7K+63.7%	$4K+1188.0%	$325
Income Tax	$2.1M+2186.3%	$90K+179.9%	-$113K+41.3%	-$193K-1697.7%	$12K-87.4%	$95K
Net Income	$3.6M+128.7%	-$12.5M+7.9%	-$13.6M+1.4%	-$13.8M-100.7%	-$6.9M+3.3%	-$7.1M
EPS (Diluted)	$0.87	$-24.25-30.7%	$-18.55	$-57.12	$-1.49	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$0	$0	$0	N/A	$0-100.0%	$20K-99.9%	$16.0M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.7M+5.4%	$2.6M+2.3%	$2.5M	N/A	$2.2M+6.7%	$2.0M+21.6%	$1.7M	N/A
SG&A Expenses	$1.4M+6.6%	$1.4M-9.1%	$1.5M	N/A	$1.4M-10.2%	$1.5M+18.6%	$1.3M	N/A
Operating Income	-$794K+66.8%	-$2.4M-2.8%	-$2.3M	N/A	-$3.6M-41.5%	-$2.5M-119.2%	$13.2M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$223K	N/A
Income Tax	-$643K-473.9%	-$112K-191.1%	$123K	N/A	$0	$0	$0	N/A
Net Income	$27K+101.2%	-$2.2M+1.8%	-$2.2M	N/A	-$3.4M-53.6%	-$2.2M-116.5%	$13.5M	N/A
EPS (Diluted)	$0.01+101.9%	$-0.54-3.8%	$-0.52	N/A	$-0.81-52.8%	$-0.53-115.3%	$3.46	N/A

KPHMW Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$36.5M+166.1%	$13.7M-26.6%	$18.7M-7.2%	$20.1M+31.5%	$15.3M+51.3%	$10.1M
Current Assets	$29.7M+527.0%	$4.7M-38.3%	$7.7M-14.6%	$9.0M+420.8%	$1.7M-60.1%	$4.3M
Cash & Equivalents	$3.8M+54.5%	$2.5M-58.8%	$6.0M-24.1%	$7.9M+562.5%	$1.2M-68.6%	$3.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$601K	$0	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	$0	$0-100.0%	$3.6M+138.0%	$1.5M
Total Liabilities	$10.7M+41.1%	$7.6M+4.6%	$7.3M+31.0%	$5.6M-0.4%	$5.6M+59.7%	$3.5M
Current Liabilities	$6.0M+267.7%	$1.6M-50.1%	$3.3M+103.3%	$1.6M-18.9%	$2.0M+40.3%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	$278K	$0
Total Equity	$25.8M+321.6%	$6.1M-46.4%	$11.4M-21.8%	$14.6M+49.8%	$9.7M+46.9%	$6.6M
Retained Earnings	-$143.4M+2.4%	-$147.0M-9.3%	-$134.5M-11.2%	-$120.9M-12.9%	-$107.1M-6.8%	-$100.2M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$29.9M-6.5%	$31.9M-6.1%	$34.0M-6.8%	$36.5M-5.3%	$38.5M-5.6%	$40.8M-3.8%	$42.4M+209.5%	$13.7M
Current Assets	$22.7M-8.3%	$24.7M-8.7%	$27.1M-8.7%	$29.7M-6.1%	$31.7M-0.6%	$31.8M-4.9%	$33.5M+606.7%	$4.7M
Cash & Equivalents	$5.5M+435.7%	$1.0M-72.7%	$3.8M-0.6%	$3.8M-32.7%	$5.6M-14.3%	$6.6M-79.0%	$31.3M+1174.1%	$2.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.2M-49.8%	$2.4M+80.8%	$1.3M+122.5%	$601K-66.3%	$1.8M+33.0%	$1.3M+606.3%	$190K	$0
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.5M-24.1%	$9.8M-4.9%	$10.3M-3.8%	$10.7M+26.5%	$8.5M+9.9%	$7.7M+2.3%	$7.5M-0.9%	$7.6M
Current Liabilities	$2.6M-19.0%	$3.2M-39.6%	$5.3M-12.2%	$6.0M+70.3%	$3.5M+113.0%	$1.7M+4.0%	$1.6M-2.5%	$1.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$22.4M+1.3%	$22.1M-6.6%	$23.7M-8.0%	$25.8M-14.2%	$30.0M-9.3%	$33.1M-5.2%	$34.9M+471.3%	$6.1M
Retained Earnings	-$147.7M0.0%	-$147.7M-1.5%	-$145.6M-1.5%	-$143.4M-3.0%	-$139.2M-2.5%	-$135.7M-1.7%	-$133.5M+9.2%	-$147.0M

KPHMW Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	$8.6M+189.6%	-$9.6M+8.4%	-$10.4M+2.3%	-$10.7M-45.9%	-$7.3M+10.3%	-$8.2M
Capital Expenditures	$6K	$0	$0-100.0%	$64K+218.1%	$20K	$0
Free Cash Flow	$8.6M+189.5%	-$9.6M+8.4%	-$10.4M+2.9%	-$10.7M-46.4%	-$7.3M+10.0%	-$8.2M
Investing Cash Flow	-$22.7M	$0-100.0%	$6K+104.1%	-$157K+35.8%	-$244K	$0
Financing Cash Flow	$15.5M+159.8%	$6.0M-30.8%	$8.6M-51.0%	$17.6M+251.8%	$5.0M+27.5%	$3.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$1.3M+66.5%	-$3.8M-40.6%	-$2.7M-20.1%	-$2.3M-344.8%	$920K+124.6%	-$3.7M-127.4%	$13.6M+627.8%	-$2.6M
Capital Expenditures	$431	N/A	N/A	-$45K	$0	N/A	N/A	$0
Free Cash Flow	-$1.3M	N/A	N/A	-$2.3M-349.7%	$920K	N/A	N/A	-$2.6M
Investing Cash Flow	$5.7M+764.3%	$664K-75.2%	$2.7M+453.7%	$483K+125.1%	-$1.9M+91.0%	-$21.2M	$0	$0
Financing Cash Flow	$0-100.0%	$265K	$0	$0	$0-100.0%	$251K-98.4%	$15.2M+3234.7%	-$486K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KPHMW Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	28.1%	N/A	N/A	N/A	-56960.5%	N/A
Net Margin	22.4%	N/A	N/A	N/A	-56901.6%-56637.4pp	-264.2%
Return on Equity	14.0%+218.8pp	-204.8%-85.7pp	-119.1%-24.6pp	-94.5%-23.9pp	-70.5%+36.6pp	-107.2%
Return on Assets	9.8%+101.1pp	-91.3%-18.5pp	-72.7%-4.3pp	-68.4%-23.6pp	-44.8%+25.3pp	-70.2%
Current Ratio	4.94+2.0	2.90+0.6	2.35-3.2	5.59+4.7	0.87-2.2	3.06
Debt-to-Equity	0.42-0.8	1.24+0.6	0.64+0.3	0.38+0.4	0.03+0.0	0.00
FCF Margin	53.4%	N/A	N/A	N/A	-60844.6%-60541.0pp	-303.6%

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-12724.4%-12807.1pp	82.6%	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-11108.2%-11192.3pp	84.1%	N/A
Return on Equity	0.1%+9.8pp	-9.7%-0.5pp	-9.3%	N/A	-11.4%-4.7pp	-6.7%-45.3pp	38.5%	N/A
Return on Assets	0.1%+6.8pp	-6.7%-0.3pp	-6.5%	N/A	-8.9%-3.4pp	-5.4%-37.1pp	31.7%	N/A
Current Ratio	8.79+1.0	7.76+2.6	5.14+0.2	4.94-4.0	8.97-10.2	19.22-1.8	21.02+18.1	2.90
Debt-to-Equity	0.33-0.1	0.440.0	0.44+0.0	0.42+0.1	0.28+0.0	0.23+0.0	0.22-1.0	1.24
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Frequently Asked Questions

What is Kiora Pharma's annual revenue?

Kiora Pharma (KPHMW) reported $16.0M in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Kiora Pharma profitable?

Yes, Kiora Pharma (KPHMW) reported a net income of $3.6M in fiscal year 2024, with a net profit margin of 22.4%.

What is Kiora Pharma's EBITDA?

Kiora Pharma (KPHMW) had EBITDA of $4.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kiora Pharma's operating margin?

Kiora Pharma (KPHMW) had an operating margin of 28.1% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.

What is Kiora Pharma's net profit margin?

Kiora Pharma (KPHMW) had a net profit margin of 22.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.

What is Kiora Pharma's return on equity (ROE)?

Kiora Pharma (KPHMW) has a return on equity of 14.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Kiora Pharma's free cash flow?

Kiora Pharma (KPHMW) generated $8.6M in free cash flow during fiscal year 2024. This represents a 189.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kiora Pharma's operating cash flow?

Kiora Pharma (KPHMW) generated $8.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Kiora Pharma's total assets?

Kiora Pharma (KPHMW) had $36.5M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Kiora Pharma's capital expenditures?

Kiora Pharma (KPHMW) invested $6K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Kiora Pharma spend on research and development?

Kiora Pharma (KPHMW) invested $7.8M in research and development during fiscal year 2024.

How many shares does Kiora Pharma have outstanding?

Kiora Pharma (KPHMW) had 3M shares outstanding as of fiscal year 2024.

What is Kiora Pharma's current ratio?

Kiora Pharma (KPHMW) had a current ratio of 4.94 as of fiscal year 2024, which is generally considered healthy.

What is Kiora Pharma's debt-to-equity ratio?

Kiora Pharma (KPHMW) had a debt-to-equity ratio of 0.42 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kiora Pharma's return on assets (ROA)?

Kiora Pharma (KPHMW) had a return on assets of 9.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Kiora Pharma's Piotroski F-Score?

Kiora Pharma (KPHMW) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kiora Pharma's earnings high quality?

Kiora Pharma (KPHMW) has an earnings quality ratio of 2.38x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Kiora Pharma cover its interest payments?

Kiora Pharma (KPHMW) has an interest coverage ratio of 210.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Kiora Pharma?

Kiora Pharma (KPHMW) scores 84 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.